No abstract

No abstract

No abstract

Background ABP 501 was evaluated in a phase 3 single-arm, open-label extension (OLE) study to collect additional safety and efficacy data in patients with rheumatoid arthritis (RA). Methods Subjects completing the final visit in the parent phase 3 randomized, double-blind, controlled equivalence study comparing the efficacy and safety of the biosimilar ABP 501 with adalimumab reference product (RP) were enrolled in this open-label extension (OLE) study. All subjects received 40 mg ABP 501 every other week for 68 weeks. Key safety endpoints included treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and anti-drug antibody (ADA) incidences. Efficacy endpoints included ACR20 (at least 20% improvement in American College of Rheumatology core set measurements from baseline) and Disease Activity Score 28-joint count C-reactive protein (DAS28-CRP) change from baseline. Results Among 466/467 patients treated with ABP 501, 229 transitioned from the ABP 501 arm of the parent study (ABP 501/ABP 501) and 237 from the adalimumab RP arm (RP/ABP 501); 412/467 (88.2%) patients completed the study. The overall TEAE incidence was 63.7% (297/466); grade ≥ 3 TEAE incidence was 9.0% (42/466). The incidence of TEAEs leading to discontinuation of investigational product was 3.6% (17/466). The SAE incidence was 9.9% (46/466). Overall, 18.2% (85/466) of subjects developed binding ADAs and 6.9% (32/466) developed neutralizing ADAs in the OLE study. The ACR20 response rate was 73.3% (340/464 subjects) at OLE baseline, and 78.8% (327/415 subjects) at week 70 of the OLE study. The overall mean DAS28-CRP change from the parent study baseline was − 2.25 at the OLE study baseline ( n = 440), − 2.36 at week 4 ( n = 463), − 2.41 at week 24 ( n = 450), − 2.55 at week 48 ( n = 433), and − 2.60 at week 70 ( n = 412). Efficacy was maintained throughout the study. Conclusions Efficacy previously demonstrated in the parent study was maintained in this OLE study with no new safety findings. Long-term safety, immunogenicity, and efficacy were similar in the ABP 501/ABP 501 and RP/ABP 501 groups. The single switch from RP to ABP 501 did not impact immunogenicity. Trial registration ClinicalTrial.gov, NCT02114931

A herbicide safener, CGA-43089 [α-(cyanomethoximino)-benzacetonitrile], has been discovered which will allow the safe use of metolachlor [2-chloro-N-(2-ethyl-6-methylphenyl)-N-(2-methoxy-1-methylethylacetamide] in grain sorghum [Sorghum bicolor(L.) Moench]. Experiments revealed that sorghum is protected from injury by metolachlor when it is applied at rates as high as 4 kg/ha. Better protection was achieved when sorghum seed were treated directly with the safener than when it was mixed with the herbicide. A CGA-43089 rate of 1.25 to 1.5 g per kg of sorghum seed was adequate for protection. Sorghum tolerance to metolachlor was maintained with CGA-43089 when metolachlor was combined with severals-triazine herbicides. Metolachlor effectively controlled several annual grasses with an increase in sorghum yield.